Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.

Abstract: The present invention is directed to Fc fusion water soluble GPCR (G-protein coupled receptor) proteins with QTY membrane regions, wherein the amino acids Q (Glutamine), T (Threonine), and Y (Tyrosine), together with other amino acids can form an alpha helical domain that mimics a transmembrane region, and the QTY code conversions render the alpha-helical segment water-soluble. Further disclosed are methods for the preparation QTY Fc receptor and methods of use thereof.

Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.

Abstract: The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor or device comprising the bioelectronic interface and methods of screening for a ligand of a GPCR.

Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.

Abstract: The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor or device comprising the bioelectronic interface and methods of screening for a ligand of a GPCR.

Abstract: The invention encompasses emulsomes coated with S-layer fusion proteins, pharmaceutical compositions and vaccines comprising the emulsomes, and methods of use thereof for immunizing a patient.

Abstract: Described are S-layer fusion proteins comprising a self-assembling domain of a S-layer protein and a viral spike protein or a fragment thereof, a pharmaceutical composition (such as a vaccine) comprising the S-layer fusion protein, and method of immunizing a patient in need thereof comprising administering the vaccine.

Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.

Abstract: The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor or device comprising the bioelectronic interface and methods of screening for a ligand of a GPCR.

Abstract: Method for the manufacturing of a supported lipid membrane comprising: providing a substrate, covered at least in part with a layer comprising proteins, glycoproteins, polypeptides and/or peptides; contacting and incubating said substrate with a solution comprising bicelles, which comprise at least one short chain and at least one long chain phospholipid and/or at least one detergent, thereby producing a supported lipid membrane; and optionally removing the lipid membrane formed on the substrate from said substrate, as well as membranes made by such method.

Abstract: The invention concerns a process for the recombinant production of S-layer proteins in gram-negative host cells. Furthermore the nucleotide sequence of a new S-layer gene and processes for the production of modified S-layer proteins are disclosed.

Abstract: The invention concerns a process for the recombinant production of S-layer proteins in gram-negative host cells. Furthermore the nucleotide sequence of a new S-layer gene and processes for the production of modified S-layer proteins are disclosed.

Abstract: The invention concerns a process for the recombinant production of S-layer proteins in gram-negative host cells. Furthermore the nucleotide sequence of a new S-layer gene and processes for the production of modified S-layer proteins are disclosed.

Abstract: Use of novel membrane crystal lattice structures with continuous pores as ultrafiltration membranes, gas separating organs and separating organs for ion exchange processes, structure for immobilizing molecules, and films as enveloping material for substances.

Abstract: A method for producing a structure comprising at least one membrane with continuous pores having a diameter range of 1 to 8 nm extending along plane, curved, cylindrical or vesicular surfaces consisting essentially of at least one layer of contiguous identical protein containing molecules which molecules are arranged to form a crystal lattice defining continous pores free of said molecules, the membranes being connected to or embedded in a support layer or the membranes being connected together to form a stable unsupported film comprising removing the cell contents from intact cells of microorganisms or breaking the intact cells and separating the membranes or membrane containing cell envelope fragments, suspending the membranes or membrane containing cell envelope fragments in a liquid medium, combining the membranes or membrane containing cell envelope fragments into a layer with a crystal lattice with continuous pores free of the protein containing molecules by depositing the membranes or membrane containi

Abstract: Use of novel membrane crystal lattice structures with continuous pores as ultrafiltration membranes, gas separating organs and separating organs for ion exchange processes structure for immobilizing molecules, and films as enveloping material for substances.

Abstract: A structure usable as an ultrafiltration membrane has membranes (20) with continuous pores which are linked to or into an appropriately porous carrier (21). Each of these membranes (20) consist of protein molecules or protein containing molecules arranged according to a two-dimensional crystal lattice, between which continuous pores of equal size and form remain free, and they are advantageously formed from molecules, which were particularly separated from cell-membranes of procaryons, by means of a recrystallization process designated as self-organization, and which are preferably deposited on or into the carrier (21) and are cross-linked with the carrier (21) intra- or intermolecularly, respectively, through foreign molecules.The structure is suitable, furthermore, for use as a separating organ for a gas separation or for an ion exchange process, as well as for use as a carrier structure for other semi-permeable membranes, such as hyperfiltration membranes.